Full Year 2025 Financial Guidance
Novavax is providing Full Year 2025 Financial Guidance for R&D plus SG&A expenses and expects to achieve the following results:
| $ in millions | Full Year 2025 (as of February 27, 2025) |
| Combined R&D and SG&A Expenses | $475 - $525 |
2025 Revenue Framework
Novavax has transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 vaccination season to Sanofi for select markets. Since Novavax is reliant on Sanofi's sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time. For 2025, Novavax expects to achieve Adjusted Licensing, Royalties and Other Revenue of between $300 million to $350 million.
| $ in millions | Full Year 2025 (as of February 27, 2025) |
| Sanofi Royalties | No guidance at this time |
| Sanofi CIC and Matrix-M Milestones | No guidance at this time |
| Product Sales | No guidance at this time |
| Adjusted Licensing, Royalties and Other Revenue 1.2,3,4,5 | $300 - $350 |
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。